Viatris (VTRS) Stock May Be Cheap Following Its 107% 1 Year Run
Viatris stock has delivered a strong 1 year run, yet its valuation checks still suggest the shares may be pricing in less optimism than that performance might imply.
- The stock has returned 107.2% over the past year, which puts recent enthusiasm front and center for anyone assessing what is already priced in.
- The recent U.S. FDA approval of the once weekly Gwyn Lo contraceptive patch can support sentiment around future revenue potential, while any execution issues in bringing new products to market remain a key risk for how long investors are willing to pay up.
- Viatris screens as undervalued on 5 of 6 valuation checks, so the broader assessment leans cheap according to our score of 5 out of 6.
The stock's next move may depend on whether Viatris is still trading at a genuine discount after such a strong 1 year performance.
Is Viatris a Bargain on Sales?
P/S is a useful cross check for Viatris because it ties the share price directly to the revenue base of its product portfolio. On this measure, Viatris trades on a P/S of 1.4x. That is well below the Pharmaceuticals industry average of about 4.8x and also below the broader peer group average of roughly 5.1x.
The fair P/S ratio implied by the model for Viatris is 3.7x, which is higher than the current 1.4x level. Despite the recent FDA approval for the Gwyn Lo contraceptive patch, the market is still pricing Viatris at a discount to what this framework suggests for a company with its mix of revenue, risk and scale.
Overall, Viatris appears undervalued on the P/S multiple, with the shares trading below the modelled fair ratio and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Viatris Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Viatris give you a clear link between the valuation puzzle above and the assumptions that would need to hold on growth, margins and earnings for Viatris' stock to be worth materially more or less than it is today, and they sit on the company’s Community page. Rather than focusing on a single multiple, each narrative sets out the key assumptions behind its view of fair value so you can compare them with the company’s actual results over time.
Community views on Viatris sit far apart, with some investors seeing a recovering cash flow story and others focusing on margin and debt pressure.
Bull case: 55% undervalued
"Viatris continued to generate massive cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments…"
Read the full Bull Case to see why Viatris could be undervalued
Bear case: 46% overvalued
"Intensifying pricing pressures from government and private insurers are expected to further compress margins across Viatris' core generic drug portfolio, especially in developed markets where reimbursement cuts and price regulations are becoming more severe and persistent, ultimately resulting in lower long-term profitability…"
Read the full Bear Case to see why Viatris could be overvalued
Do you think there's more to the story for Viatris? Head over to our Community to see what others are saying!
The Bottom Line
Viatris still screens as undervalued on market multiples, with the current pricing implying a discount to peers and to the modelled fair P/S ratio. That points to some headroom if the market gains more confidence in the company’s revenue mix and balance of risk and scale. The key question from here is whether execution on new products, including Gwyn Lo, and management of margin and debt pressures are strong enough for that discount to close rather than prove justified as a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com